 |
News releases
Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.
To automatically receive future news releases, please go to the News
subscription service page.
2010
- 2009
- 2008
- [2007]
- 2006
- 2005
- 2004
- 2003
- 2002
(click to view the full text)
|
December 4, 2007
Æterna Zentaris to Present at Upcoming BMO Capital Markets Focus on Healthcare Conference and RBC Capital Markets Healthcare Conference in New York |
December 3, 2007
Æterna Zentaris Sells Echelon Biosciences to Frontier Scientific |
November 14, 2007
Æterna Zentaris Announces Completion of Patient Enrollment for Multi-Center Phase 2 Trial with Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer |
November 6, 2007
Æterna Zentaris Reports Third Quarter 2007 Financial and Operating Results |
October 31, 2007
Æterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007 |
October 30, 2007
Æterna Zentaris to Present at Upcoming 18th Annual CIBC World Markets Healthcare Conference and at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York |
October 25, 2007
Æterna Zentaris to Further Develop Three Follow-up Multi targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment |
October 2, 2007
Æterna Zentaris Announces Outcome of Management’s Strategic Review |
September 27, 2007
Æterna Zentaris to Announce Outcome of Management’s Strategic Review |
September 26, 2007
Æterna Zentaris to Present at Upcoming William Blair & Company Small-Cap Growth Stock Conference in New York and BioContact in Québec City |
September 20, 2007
Æterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York |
August 16, 2007
Æterna Zentaris Completes Management Team with the Appointment of Chief Medical Officer |
August 14, 2007
Æterna Zentaris appoints Jürgen Ernst Chairman of the Board of Directors and David J. Mazzo, Ph.D. a Board Member |
August 14, 2007
Æterna Zentaris Reports Second Quarter 2007 Financial and Operating Results |
August 6, 2007
Æterna Zentaris to Announce Second Quarter 2007 Financial and Operating Results on August 14, 2007 |
August 2, 2007
Æterna Zentaris to Present at Upcoming 27th Annual Canaccord Adams Global Growth Conference in Boston |
June 4, 2007
Æterna Zentaris Partner Keryx Presents Phase 1 and
Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting |
June 4, 2007
Æterna Zentaris Presents Detailed Phase 1 Results for
Anti-Cancer Compound AEZS-108 at ASCO Meeting |
May 23, 2007
Æterna Zentaris’ Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting |
May 9, 2007
Æterna Zentaris to Present at Upcoming Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco |
May 8, 2007
Æterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights from Solvay for Cetrorelix in Endometriosis Indication |
May 7, 2007
Æterna Zentaris Bolsters Management Team with Two Key Positions Named |
May 2, 2007
Æterna Zentaris Reports First Quarter 2007 Financial and Operating Results |
April 30, 2007
Æterna Zentaris to Hold Annual Shareholder Meeting on May 2, 2007 at the Sheraton Centre in Montreal |
April 25, 2007
Æterna Zentaris to Announce First Quarter 2007 Financial and Operating Results on May 2, 2007 |
April 19, 2007
Æterna Zentaris Reports First Patients Treated with Cetrorelix for Phase 3 Program in BPH |
April 17, 2007
Æterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in
Los Angeles |
April 16, 2007
Æterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles |
April 13, 2007
Æterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles |
April 5, 2007
Æterna Zentaris to Present at Upcoming CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York |
March 26, 2007
Æterna Zentaris Announces Appointment of New President and CEO |
March 22, 2007
Æterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial |
March 21, 2007
Æterna Zentaris to Host Live Webcast of Analyst and Investor Meeting Today |
March 5, 2007
Æterna Zentaris Reports Fourth Quarter and Full-Year 2006 Financial and Operating Results |
February 27, 2007
Æterna Zentaris to Announce Fourth Quarter and Full-Year 2006 Financial and Operating Results on March 5, 2007 |
February 12, 2007
Æterna Zentaris To File Restated Interim 2006 Third Quarter Financials |
February 6, 2007
Æterna Zentaris to Present at Upcoming BIO CEO & Investor Conference in New York |
January 26, 2007
Æterna Zentaris Discloses New In Vivo Data for ZEN-012 at the 7th Joint Conference of the AACR and JCA |
January 8, 2007
Æterna Zentaris Initiates Phase 1 Trial for ZEN-012, a new small molecule oral anti-cancer drug - IND accepted by FDA |
January 8, 2007
Æterna Zentaris Initiates First Study of Phase 3 Program with Cetrorelix in BPH - 600 Patient Trial Conducted in the United States and Canada |
January 3, 2007
Æterna Zentaris Completes Distribution of Remaining Shares of Atrium Biotechnologies |
 |
 |
